Fertility-sparing tx feasible in early endometrial cancer

October 30, 2012
Fertility-sparing tx feasible in early endometrial cancer
For women with early-stage endometrial cancer and atypical complex hyperplasia, fertility-sparing treatment seems feasible, according to research published in the October issue of the American Journal of Obstetrics & Gynecology.

(HealthDay)—For women with early-stage endometrial cancer (EC) and atypical complex hyperplasia (ACH), fertility-sparing treatment seems feasible, according to research published in the October issue of the American Journal of Obstetrics & Gynecology.

Ioannis D. Gallos, M.D., from the Birmingham Women's Hospital in the United Kingdom, and colleagues conducted a systematic review and meta-analysis to examine the regression, relapse, and live birth rates for women with EC and ACH who underwent fertility-sparing treatment. A total of 34 observational studies, involving 408 women with EC and 151 women with ACH were included.

The researchers found that, for EC, fertility-sparing treatment achieved a pooled regression rate of 76.2 percent, a relapse rate of 40.6 percent, and a live birth rate of 28 percent. The corresponding figures for ACH were 85.6, 26, and 26.3 percent. During follow-up, 3.6 percent of women were diagnosed with ovarian (concurrent or metastatic), 1.9 percent of women (10 women) progressed to disease higher than stage I EC, and two of these 10 died.

"In conclusion, this review of observational studies found a high chance of disease regression and encouraging live birth rates of early-stage EC and ACH with fertility-sparing treatment followed by assisted reproduction," the authors write. "Our systematic examination of the published literature confirms that there is only moderate-quality observational evidence to inform clinical practice, and results should be interpreted with caution."

Explore further: Confusion about emergency contraception access common

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Confusion about emergency contraception access common

March 26, 2012
(HealthDay) -- While most pharmacies report having emergency contraception (EC) in stock, misinformation regarding what age women can take it without a prescription is common, according to a study published online March 26 ...

Fertility treatment: Safer drug for women leads to same live birth rate

May 11, 2011
With new information available, authors of a Cochrane Systematic Review have revised their conclusions about the relative effectiveness of two different treatments used to help women become pregnant. They now conclude that ...

Few young women with cancer take steps to preserve fertility during treatments

March 26, 2012
A new study has found that very few young women with cancer take steps to preserve their fertility while undergoing cancer therapy. Also, certain groups of young women are more likely to do so than others. Published early ...

ART live-birth rates can approach natural fecundity

June 28, 2012
(HealthDay) -- During assisted reproductive technology, increasing maternal age and number of cycles is linked to lower live-birth rates with the use of autologous oocytes, but not donor oocytes, according to a study published ...

‘Infertile’ women may just need longer to conceive

February 20, 2012
(Medical Xpress) -- One-in-four women with a history of infertility can still end up having a baby without treatment, a new study from The University of Queensland (UQ) shows.

Recommended for you

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

A metabolic treatment for pancreatic cancer?

August 15, 2017
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.